Literature DB >> 6298271

Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.

R J Wallace, J M Swenson, V A Silcox, R C Good.   

Abstract

Disk diffusion is one method of susceptibility testing of the Mycobacterium fortuitum complex to antibacterial agents. We utilized disks of polymyxin B (300 U), amikacin, and kanamycin to determine whether they could also be used for species identification when compared with standard biochemical methods. With the polymyxin disk, 100% of 75 M. fortuitum strains produced zones of inhibition, whereas none (0%) of 58 Mycobacterium chelonei subspecies abscessus and chelonei strains had any zone of inhibition. With the amikacin disk, 99% of M. fortuitum biovariant fortuitum had zones of greater than or equal to 30 mm compared with 6% of M. chelonei. The rare M. chelonei-like organisms gave variable results, and 42% of the unnamed "third group" biovariant of M. fortuitum exhibited an unusual but diagnostic pattern of small zone sizes to amikacin and no zone to kanamycin. The kanamycin disk was otherwise not helpful, although it resulted in larger zone sizes for M. chelonei than did amikacin. Thus, disk diffusion susceptibilities which include these disks (especially polymyxin) will provide presumptive evidence of species as well as susceptibility data.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298271      PMCID: PMC272529          DOI: 10.1128/jcm.16.6.1003-1006.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Enzymatic and immunological characterization of the Mycobacterium fortuitum complex.

Authors:  B P Binko; W R Bartholomew
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

2.  Simple, new test for rapid differentiation of the Mycobacterium fortuitum complex.

Authors:  M J Casal; F C Rodriguez
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

3.  Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  R J Wallace; D B Jones; K Wiss
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

4.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.

Authors:  J M Swenson; C Thornsberry; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

5.  A fluorigenic substrate for the rapid differentiation of Mycobacterium fortuitum from Mycobacterium chelonei on the basis of heat stable esterase activity.

Authors:  J M Grange
Journal:  Tubercle       Date:  1977-09

6.  Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

Authors:  R J Wallace; J R Dalovisio; G A Pankey
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

7.  Differential identification of Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  H L David; I Traore; A Feuillet
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

8.  Antimicrobial susceptibility testing of Mycobacterium fortuitum complex.

Authors:  D F Welch; M T Kelly
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

9.  Identification of clinically significant Mycobacterium fortuitum complex isolates.

Authors:  V A Silcox; R C Good; M M Floyd
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

10.  In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.

Authors:  J R Dalovisio; G A Pankey
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

View more
  12 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; June Brown; Arnold G Steigerwalt; Leslie Hall; Gail Woods; Joann Cloud; Linda Mann; Rebecca Wilson; Christopher Crist; Kenneth C Jost; Dorothy E Byrer; Jane Tang; Jason Cooper; Elena Stamenova; Brian Campbell; Joyce Wolfe; Christine Turenne
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria.

Authors:  P W Wright; R J Wallace; N W Wright; B A Brown; D E Griffith
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

5.  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

Authors:  R J Wallace; V A Silcox; M Tsukamura; B A Brown; J O Kilburn; W R Butler; G Onyi
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

6.  Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.

Authors:  B A Brown; R J Wallace; G Onyi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  Clinical and laboratory features of Mycobacterium mageritense.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Leslie Hall; Glenn Roberts; Rebecca W Wilson; Linda B Mann; Christopher J Crist; Sher H Chiu; Robbie Dunlap; Maria J Garcia; J Todd Bagwell; Kenneth C Jost
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

8.  Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.

Authors:  L C Steele; R J Wallace
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

9.  Molecular and physiological effects of mycobacterial oxyR inactivation.

Authors:  Eileen Pagán-Ramos; Sharon S Master; Christopher L Pritchett; Renate Reimschuessel; Michele Trucksis; Graham S Timmins; Vojo Deretic
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

10.  In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; W R Thayer; J A Coutu; R S Merkal
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.